By Dr Alla Dolnikov

Book Chapters

Xu N; Tse B; Yang L; Tang TCY; Haber M; Micklethwaite K; Dolnikov A, 2022, 'Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy: A Recent Study', in Current Innovations in Medicine and Medical Science Vol. 3, Book Publisher International (a part of SCIENCEDOMAIN International), pp. 61 - 87, http://dx.doi.org/10.9734/bpi/cimms/v3/7736f

Ko KH; Nordon R; O Brien TA; Symonds G; Dolnikov A, 2017, 'Ex vivo expansion of hematopoietic stem cells to improve engraftment in stem cell transplantation', in Methods in Molecular Biology, pp. 301 - 311, http://dx.doi.org/10.1007/978-1-4939-6603-5_19

Klamer G; Shen S; Xu N; A. O`Brien T; Dolnikov A, 2015, 'Strategies to Improve Immune Reconstitution After Haematopoietic Stem Cell Transplantation', in Frontiers in Stem Cell and Regenerative Medicine Research, BENTHAM SCIENCE PUBLISHERS, pp. 30 - 64, http://dx.doi.org/10.2174/9781608059942115010004

Dolnikov A; O'Brien TA; Xu N; Shen S; Klamer G, 2014, 'Strategies to improve immune reconstitution after haematopoeitic stem cell transplantation.', in Rahman A; Anjum S (ed.), Frontiers in Stem Cell and Regenerative Medicine Research, vol. 1, Bentham Science, pp. 30 - 64, http://dx.doi.org/10.2174/97816080599421150101

Ko K; Nordon R; O Brien T; Symonds G; Dolnikov A, 2011, 'Ex Vivo Expansion of Haematopoietic Stem Cells to Improve Engraftment in Stem Cell Transplantation', in Humana Press (ed.), Cell Cycle Synchronization, Springer, New York, pp. 249 - 260, http://dx.doi.org/10.1007/978-1-61779-182-6_17

Journal articles

Moles E; Howard CB; Huda P; Karsa M; McCalmont H; Kimpton K; Duly A; Chen Y; Huang Y; Tursky ML; Ma D; Bustamante S; Pickford R; Connerty P; Omari S; Jolly CJ; Joshi S; Shen S; Pimanda JE; Dolnikov A; Cheung LC; Kotecha RS; Norris MD; Haber M; de Bock CE; Somers K; Lock RB; Thurecht KJ; Kavallaris M, 2023, 'Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia', Science translational medicine, 15, pp. eabm1262 - eabm1262, http://dx.doi.org/10.1126/scitranslmed.abm1262

Tang TCY; Xu N; Nordon R; Haber M; Micklethwaite K; Dolnikov A, 2022, 'Donor T cells for CAR T cell therapy', Biomarker Research, 10, http://dx.doi.org/10.1186/s40364-022-00359-3

Sutrave G; Xu N; Tang TCY; Dolnikov A; Gloss B; Gottlieb DJ; Micklethwaite KP; Gowrishankar K, 2022, 'Characterizing piggyBat—a transposase for genetic modification of T cells', Molecular Therapy - Methods and Clinical Development, 25, pp. 250 - 263, http://dx.doi.org/10.1016/j.omtm.2022.03.012

Chen J; Nelson C; Wong M; Tee AE; Liu PY; La T; Fletcher JI; Kamili A; Mayoh C; Bartenhagen C; Trahair TN; Xu N; Jayatilleke N; Wong M; Peng H; Atmadibrata B; Cheung BB; Lan Q; Bryan TM; Mestdagh P; Vandesompele J; Combaret V; Boeva V; Wang JY; Janoueix-Lerosey I; Cowley MJ; MacKenzie KL; Dolnikov A; Li J; Polly P; Marshall GM; Reddel RR; Norris MD; Haber M; Fischer M; Zhang XD; Pickett HA; Liu T, 2021, 'Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy', Clinical Cancer Research, 27, pp. 1438 - 1451, http://dx.doi.org/10.1158/1078-0432.CCR-20-3044

Xu N; Tse B; Yang L; Tang TC; Haber M; Micklethwaite K; Dolnikov A, 2021, 'Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy', IMMUNOTARGETS AND THERAPY, 10, pp. 123 - 140, http://dx.doi.org/10.2147/ITT.S296161

C. Y. Tang T; Xu N; Dolnikov A, 2020, 'Targeting the immune-suppressive tumor microenvironment to potentiate CAR T cell therapy', Cancer Reports and Reviews, 4, http://dx.doi.org/10.15761/crr.1000203

Dolnikov A; David C. Bishop, Ning Xu, Benjamin Tse, Tracey A. O’Brien, David J. Gottlieb, Alla , 2018, 'PiggyBac-engineered T-cells expressing CD19-specific CARs that lack IgG1 Fc spacers have potent activity against B-ALL xenografts.', Molecular Therapy, 26, pp. 1883 - 1895, http://dx.doi.org/10.1016/j.ymthe.2018.05.007

Dolnikov A; Xu N; Tse B; Shen S; O'Brien T, 2018, 'Bromodomain inhibitor jq1 modulates immune suppressive pathways in neuroblastoma and enhances CARGD2T cell therapy', Cytotherapy, 20, pp. S97 - S97, http://dx.doi.org/10.1016/j.jcyt.2018.02.285

Dolnikov A; Xu N; Tse B; O'Brien T, 2018, 'Epigenetic agent modulates tumour microenvironment and potentiates cart cell therapy', Cytotherapy, 20, pp. S97 - S97, http://dx.doi.org/10.1016/j.jcyt.2018.02.284

Xu N; Shen S; Dolnikov A, 2017, 'Increasing Stem Cell Dose Promotes Posttransplant Immune Reconstitution', Stem cells and development, 26, pp. 461 - 470, http://dx.doi.org/10.1089/scd.2016.0186

Dolnikov A, 2016, 'Haematopoietic Stem Cell Transplants Enhance CART Cell Expansion and Persistence in Xenograft Mouse Model', Cytotherapy, 18, pp. S98 - S98, http://dx.doi.org/10.1016/j.jcyt.2016.03.200

Dolnikov A; Yang S; Shen S; Xu N; Chaudhry K; Nordon R; O'Brien T, 2016, 'Prolonging CART Cell Persistence Using Conditioning with 5-Azacytidine', Cytotherapy, 18, pp. S98 - S98, http://dx.doi.org/10.1016/j.jcyt.2016.03.201

Shen S; Xu N; Yang S; O'Brien T; Dolnikov A, 2016, 'Stem Cell Approach to Generate Chimeric Antigen Receptor Modified Immune Effector Cells to Treat Cancer', Cytotherapy, 18, pp. S101 - S101, http://dx.doi.org/10.1016/j.jcyt.2016.03.211

Shen S; Dolnikov A; O'Brien T, 2016, 'Use of HDACi and PD-1/PD-L1 Blockade to Enhance Cytolytic Activity of Ex Vivo Expanded NK Cells Against Neuroblastoma', Cytotherapy, 18, pp. S101 - S101, http://dx.doi.org/10.1016/j.jcyt.2016.03.212

Shen S; Xu N; Klamer G; Ko KH; Khoo M; Ma D; Moore J; O'Brien TA; Dolnikov A, 2015, 'Small-molecule inhibitor of glycogen synthase kinase 3β 6-bromoindirubin-3-oxime inhibits hematopoietic regeneration in stem cell recipient mice', Stem Cells and Development, 24, pp. 724 - 736, http://dx.doi.org/10.1089/scd.2014.0230

Dolnikov A; Shen S; Klamer G; Joshi S; Xu N; Yang L; Micklethwaite K; O'Brien TA, 2015, 'Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia', Experimental Hematology, 43, pp. 1001 - 1014.e5, http://dx.doi.org/10.1016/j.exphem.2015.08.006

Kim PY; Tan O; Diakiw SM; Carter D; Sekerye EO; Wasinger VC; Liu T; Kavallaris M; Norris MD; Haber M; Chesler L; Dolnikov A; Trahair TN; Cheung NK; Marshall GM; Cheung BB, 2014, 'Identification of plasma Complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach', Journal of Proteomics, 96, pp. 1 - 12, http://dx.doi.org/10.1016/j.jprot.2013.10.032

Dolnikov A; Xu N; Shen S; Song E; Holmes T; Klamer G; O'Brien TA, 2014, 'GSK-3β inhibition promotes early engraftment of ex vivo-expanded haematopoietic stem cells', Cell Proliferation, 47, pp. 113 - 123, http://dx.doi.org/10.1111/cpr.12092

Shen S; Xu N; Klamer G; O'Brien TA; Dolnikov A, 2013, 'NOVEL APPROACH TO GENERATE CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS USING GENETICALLY MODIFIED T CELL PRECURSORS', CYTOTHERAPY, 15, pp. S54 - S54, http://dx.doi.org/10.1016/j.jcyt.2013.01.211

Klamer G; Shen S; Song E; Rice AM; Knight R; Lindeman R; O'Brien TA; Dolnikov A, 2013, 'GSK3 inhibition prevents lethal GVHD in mice', Experimental Hematology, 41, http://dx.doi.org/10.1016/j.exphem.2012.09.005

Shen S; Xu N; O'Brien TA; Dolnikov A; Klamer G, 2013, 'GSK-3β inhibition preserves naive T cell phenotype in bone marrow reconstituted mice', Experimental Hematology, 41, pp. 1016 - 1027, http://dx.doi.org/10.1016/j.exphem.2013.08.006

Holmes TA; Yan F; Ko K; Nordon RE; Song YE; O Brien T; Dolnikov A, 2012, 'Ex vivo expansion of cord blood progenitors impairs their short-term and long-term repopulating activity associated with transcriptional dysregulation of signalling networks', Cell Proliferation, 45, pp. 266 - 278, http://dx.doi.org/10.1111/j.1365-2184.2012.00813.x

Ko K; Holmes TA; Palladinetti P; Song E; Nordon RE; O Brien T; Dolnikov A, 2011, 'GSK-3β Inhibition Promotes Engraftment of Ex Vivo-Expanded Hematopoietic Stem Cells and Modulates Gene Expression', Stem Cells, 29, pp. 108 - 118, http://dx.doi.org/10.1002/stem.551

Palladinetti P; Symonds G; Dolnikov A, 2011, 'IRF1 (interferon regulatory factor 1)', Atlas of Genetics and Cytogenetics in Oncology and Haematology, http://dx.doi.org/10.4267/2042/38570

Song EY; Palladinetti P; Klamer G; Ko K-H; Lindeman R; O'Brien TA; Dolnikov A, 2010, 'Glycogen synthase kinase−3β inhibitors suppress leukemia cell growth', Experimental Hematology, 38, pp. 908 - 921, http://dx.doi.org/10.1016/j.exphem.2010.06.001

Klamer G; Song EY; Ko K; O Brien T; Dolnikov A, 2010, 'Using Small Molecule GSK3 beta Inhibitors to Treat Inflammation', Current Medicinal Chemistry: Cardiovascular and Hematological Agents, 17, pp. 2873 - 2881, http://dx.doi.org/10.2174/092986710792065090

Dolnikov A; Ko K-H; Song E; Holmes T; O’Brien TA, 2008, 'GSK-3β Inhibition Activates WNT, Delays Division and Preserves the Function in Hematopoietic Stem Cell', Blood, 112, pp. 616 - 616, http://dx.doi.org/10.1182/blood.v112.11.616.616

Holmes TA; O Brien T; Knight RJ; Lindeman R; Shen S; Song YE; Symonds GP; Dolnikov A, 2008, 'Glycogen synthase kinase-3 beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth', Stem Cells, 26, pp. 1288 - 1297, http://dx.doi.org/10.1634/stemcells.2007-0600

Choo A; Palladinetti P; Holmes TA; Basu S; Shen S; Lock RB; O Brien T; Symonds GP; Dolnikov A, 2008, 'siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth.', International Journal of Oncology, 33, pp. 175 - 183

Holmes TA; O Brien T; Knight RJ; Lindeman R; Symonds G; Dolnikov A, 2008, 'The role of glycogen synthase kinase-3 beta in normal haematopoiesis, angiogenesis and leukaemia', Current Medicinal Chemistry: Cardiovascular and Hematological Agents, 15, pp. 1493 - 1499, http://dx.doi.org/10.2174/092986708784638834

O'Brien TA; Hohnes T, 2007, 'Glycogen synthase kinase-3B regulates ex-vivo expansion and engraftment of umbilical cord blood hematopoietic stem cells through activation of WNT signalling', BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 13, pp. 1395 - 1395, http://dx.doi.org/10.1016/j.bbmt.2007.08.016

Shen S; Passioura TJ; Symonds GP; Dolnikov A, 2007, 'N-ras oncogene-induced gene expression in human hematopoietic progenitor cells: Upregulation of p16INK4a and p21CIP1/WAF1 correlates with myeloid differentiation', Experimental Hematology, 35, pp. 908 - 919, http://dx.doi.org/10.1016/j.exphem.2007.02.011

Knight RJ; O’Brien TA; Lindeman R; Dolnikov A, 2006, 'Mutant Ras-Expressing Fibroblasts Induce Expansion of Circulating Angio- and Lymphangiogenic Precursor Cells: Potential Role in Tumour Vascularisation.', Blood, 108, pp. 1331 - 1331, http://dx.doi.org/10.1182/blood.v108.11.1331.1331

Knight RJ; O’Brien TA; Lindeman R; Dolnikov A, 2006, 'Novel Role of Activated Ras in Leukaemogenesis: Induction of Angiogenesis.', Blood, 108, pp. 1313 - 1313, http://dx.doi.org/10.1182/blood.v108.11.1313.1313

Choo A; Palladinetti P; Passioura TJ; Shen S; Symonds GP; Dolnikov A, 2006, 'The role of IRF1 and IRF2 transcription factors in leukaemogenesis', Current Gene Therapy, 6, pp. 543 - 550, http://dx.doi.org/10.2174/156652306778520683

Shen S; Passioura ; Choo A; Symonds G; Dolnikov A, 2005, 'Targeting the IRF2 transcription factor to inhibit leukaemic cell growth', Journal of Gene Medicine, 7, pp. 1135 - 1135, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000231477900071&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Passioura TJ; Shen S; Symonds GP; Dolnikov A, 2005, 'A retroviral library genetic screen identitifies IRF-2 as an inhabitor of N-ras induced growth suppervision in leukemai cells', Oncogene, 24, pp. 7327 - 7336, http://dx.doi.org/10.1038/sj.onc.1208877

Shen S; Passioura TJ; Choo A; Symonds GP; Dolnikov A, 2005, 'Mutant N-ras activation in primary human hemaopoietic progenitor cells: biologic, phenotypic and genetic sequelae', EJC Supplements, 3, pp. 285 - 285, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000247564801146&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Passioura TJ; Dolnikov A; Shen S; Symonds GP, 2005, 'N-ras induced growth suppression of myeloid cells is mediated by IRF-1', Cancer research, 65, pp. 797 - 804

Shen SC; Dolnikov A; Passioura TJ; Millington M; Wotherspoon S; Rice AM; Mackenzie K; Symonds GP, 2004, 'Mutant N-ras preferentially drives human CD34+ hematopoietic progenitor cells into myeloid proliferation both in vitro and in the NOd/SCID mouse.', Experimental Hematology, 32, pp. 852 - 860, http://dx.doi.org/10.1016/j.exphem.2004.06.001

Wotherspoon S; Dolnikov A; Symonds GP; Nordon RE, 2004, 'Susceptibility of cell populations to transduction by retroviral vectors', Journal of Virology, 78, pp. 5097 - 5102, http://dx.doi.org/10.1128/JVI.78.10.5097-5102.2004

Dolnikov A; Wotherspoon S; Millington M; Symonds G, 2003, 'Retrovirus vector production and transduction: Modulation by the cell cycle', Journal of General Virology, 84, pp. 3131 - 3141, http://dx.doi.org/10.1099/vir.0.19099-0

Dolnikov A; Shen S; Millington M; Passioura T; Pedler M; Rasko JEJ; Symonds G, 2003, 'A sensitive dual-fluorescence reporter system enables positive selection of ras suppressors by suppression of ras-induced apoptosis', Cancer Gene Therapy, 10, pp. 745 - 754, http://dx.doi.org/10.1038/sj.cgt.7700603

Dolnikov A; Shen S; Passioura TJ; Symonds GP, 2003, 'Genetic control of hematopoietic stem cell biology and leukemogenesis', Blood, 102, pp. 332A - 332A, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000186536701194&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Dolnikov A; Shen SC; Passioura TJ; Symonds GP, 2003, 'Bone marrow reconstituiton as a relevant model of genetically programmd leukemia', Current Medicinal Chemistry: Cardiovascular and Hematological Agents, 1, pp. 83 - 97, http://dx.doi.org/10.2174/1568016033477531

Back to profile page